Interestingly, treatment of B16 melanoma, MC38 colon cancer and sarcoma cancer cell lines in vitro with anti-PD-L1 antibodies was shown to reduce aerobic glycolysis mechanisms, including reduced glycolysis enzymes and Akt phosphorylation, indicating a tumor intrinsic role for PD-L1 in enhancing tumor glycolysis. This evidence concerns the gene CD274 and melanoma.